Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

Summary

This pilot phase II trial studies how well carfilzomib works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bone marrow or blood cell transplant, usually occurring more than three months after transplant, in which donor cells damage the host tissue. Carfilzomib may be an effective treatment for chronic graft-versus-host disease.

Timeline

Start

2015-11-12

Primary completion

2018-02-19

Completion

2018-09-12

Drugs

Indications